Werewolf Therapeutics, Inc.

HOWL

US95075A1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:09:22 2024-05-17 pm EDT			5-day change	1st Jan Change
4.73 ^USD	-3.07%		-5.05%	+24.22%

May. 03	Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	CI

Elise Wang Joins Werewolf Therapeutics, Inc.'s Board

January 07, 2021 at 07:00 am EST

Werewolf Therapeutics, Inc. announced that in connection with the closing of the financing, Elise Wang of Deerfield Management joined the Board of Directors of Werewolf.

Latest news about Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 03	CI
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	Apr. 23	CI
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	Apr. 05	CI
JMP Securities Starts Werewolf Therapeutics With Market Outperform Rating, $12 Price Target	Apr. 03	MT
Werewolf Therapeutics' Q4 Net Loss Narrows	Mar. 07	MT
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	Jan. 04	CI
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Werewolf Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Nov. 03	MT
Sector Update: Health Care	Nov. 03	MT
Top Midday Gainers	Nov. 03	MT
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting	Nov. 03	CI
Werewolf Therapeutics, Inc. to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's 38th Annual Meeting	23-10-31	CI
Top Premarket Decliners	23-09-25	MT
Wedbush Starts Werewolf Therapeutics at Outperform With $9 Price Target	23-08-24	MT
Werewolf Therapeutics, Inc. Announces the Investigational New Drug Application Clearance of JZP898 (Formerly Wtx-613), an Engineered IFN Indukine Molecule	23-08-10	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Werewolf Therapeutics, Inc. Anticipates Multiple Catalysts as the Company Progress the Company's Two Clinical Stage Programs, WTX-124 and WTX-330	23-03-23	CI
North American Morning Briefing : Traders Reassess -2-	23-03-23	DJ
Werewolf Therapeutics Doses First Patient in Phase 1 Study of Potential Solid Tumor Drug	23-02-24	MT

Chart Werewolf Therapeutics, Inc.

Duration

Period

More charts

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the bodyâs immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Sector

Biotechnology & Medical Research

Calendar

2024-05-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Werewolf Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.88 USD

Average target price

12 USD

Spread / Average Target

+145.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WEREWOLF THERAPEUTICS, INC.	+24.22%	212M
MODERNA, INC.	+32.73%	50.85B
IQVIA HOLDINGS INC.	+0.07%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.83%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-22.26%	19.13B
BIO-TECHNE CORPORATION	+8.37%	13.05B
MEDPACE HOLDINGS, INC.	+27.21%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.42%	12.08B

Other Biotechnology & Medical Research

Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Biotechnology & Medical Research

Elise Wang Joins Werewolf Therapeutics, Inc.'s Board

Latest news about Werewolf Therapeutics, Inc.

Chart Werewolf Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for Werewolf Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research